Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Creabilis Itching To Start Phase III Tests Of Lead Asset For Chronic Pruritus

This article was originally published in Scrip

Executive Summary

Keen to make up for lost time, dermatology specialist Creabilis Ltd is using positive Phase IIb data to advance its lead anti-itch product CT327, a novel topical TrkA kinase inhibitor, on to Phase III trials in psoriasis patients which, if successful, should open the way for regulatory filing in mid-2018 for a condition where there is no approved standard of care.


Related Content

Itch-Focused Creabilis Finally Secures Its Future Through US Sale
Regeneron Revives NGF Inhibitor With Phase II/III Data; Safety Issue Remains